Open AccessNecrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report
Author(s) -
A Gonzaga-López,
Joaquín Manuel Muñoz Rodríguez,
Ana Ruiz-Casado
Publication year - 2017
Publication title -
annals of the royal college of surgeons of england
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.39
H-Index - 63
eISSN - 1478-7083
pISSN - 0035-8843
DOI - 10.1308/rcsann.2017.0143
Subject(s) - medicine , folfiri , aflibercept , bevacizumab , colorectal cancer , ramucirumab , necrotising fasciitis , folinic acid , fasciitis , surgery , irinotecan , gastroenterology , oncology , cancer , chemotherapy
Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier's gangrene.